福元医药参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - The company Fu Yuan Pharmaceutical (601089.SH) announced participation in the national organized procurement for drugs whose agreements are expiring, with selected products including Ezetimibe tablets, which are expected to positively impact future operating performance despite a decrease in sales prices [1] Group 1: Procurement Participation - The company participated in the national organized procurement for drugs with expiring agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions signing procurement contracts based on the selected results [1] Group 2: Market Impact - Selected products in this procurement, including Ezetimibe tablets, are anticipated to have a decrease in sales prices [1] - The company aims to stabilize its existing market share and potentially increase market penetration due to brand influence and reliable supply capabilities [1] - The positive impact on the company's future operating performance is expected as a result of these developments [1]